Multiple sclerosis trials recruiting in New Jersey

All Multiple sclerosis trials nationally

Cities in New Jersey

Recruiting trials in New Jersey

• A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
  NCT06197685 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · New Jersey: East Hanover
• A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
  NCT07779460 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · New Jersey: East Hanover
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Bridgewater, Cherry Hill, Freehold, Livingston
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · New Jersey: Livingston
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New Jersey: Hackensack, New Brunswick
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · New Jersey: Teaneck
• Gait Adaptation Study
  NCT07660601 · Phase: Early Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New Jersey: Newark
• Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
  NCT04855825 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · New Jersey: West Orange
• Multiple Sclerosis Implementation Network (Registry)
  NCT07415824 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Cherry Hill
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · New Jersey: Teaneck
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
  NCT05285891 · Phase: Phase 4 · Ages: 18 Years to 55 Years · Sex: All (male and female) · New Jersey: Livingston
• Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
  NCT07732907 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · New Jersey: Lawrenceville
• Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
  NCT07614321 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · New Jersey: Morristown
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
  NCT06408259 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · New Jersey: New Brunswick, Teaneck
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: New Brunswick
• Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community
  NCT06608797 · Phase: Not applicable (e.g. observational or device study) · Ages: 19 Years to 65 Years · Sex: All (male and female) · New Jersey: East Hanover